Your browser doesn't support javascript.
loading
Characterization model of the post COVID-19 condition based on immunological, biochemical, and cytokine markers.
Oliván-Blázquez, Bárbara; Bona-Otal, Marta; Méndez-López, Fátima; Lerma-Irureta, David; García-Izuel, Paula; Ibáñez-Ruiz, Jesús; Montolío, Alberto; Ruiz-Herreros, María; Godino, Javier; Jimeno-Beltran, Beatriz; Encabo-Berzosa, María Del Mar; Arenaz, Izaskun; Medel-Martínez, Ana; Casado-Vicente, Verónica; Coiras, Mayte; Tellería-Orriols, Carlos; Schoorlemmer, Jon; Magallón-Botaya, Rosa.
  • Oliván-Blázquez B; Department of Psychology and Sociology, University of Zaragoza, Zaragoza, Spain.
  • Bona-Otal M; Aragonese Primary Care Research Group (GAIAP), Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain.
  • Méndez-López F; Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Carlos III Health Institute, Madrid, Spain.
  • Lerma-Irureta D; Navarre Health Service, Pamplona, Spain.
  • García-Izuel P; Aragonese Primary Care Research Group (GAIAP), Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain.
  • Ibáñez-Ruiz J; Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Carlos III Health Institute, Madrid, Spain.
  • Montolío A; Aragonese Primary Care Research Group (GAIAP), Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain.
  • Ruiz-Herreros M; Department of Medicine, Psychiatry and Dermatology, University of Zaragoza, Zaragoza, Spain.
  • Godino J; Biocomputing Unit, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain.
  • Jimeno-Beltran B; Biocomputing Unit, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain.
  • Encabo-Berzosa MDM; Tarazona Primary Health Care Center, Aragonese Healthcare Service (SALUD), Zaragoza, Spain.
  • Arenaz I; Cell Separation and Flow Cytometry Core, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain.
  • Medel-Martínez A; Cell Separation and Flow Cytometry Core, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain.
  • Casado-Vicente V; Biobank of the Aragon Health System, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain.
  • Coiras M; Biobank of the Aragon Health System, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain.
  • Tellería-Orriols C; Placental Pathophysiology & Fetal Programming Research Group, Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain.
  • Schoorlemmer J; Parquesol University Health Center, Castilla y León Health Service (SACYL), University Teaching Unit of Family and Community Medicine, University of Valladolid, Valladolid, Spain.
  • Magallón-Botaya R; Immunopathology and Viral Reservoir Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
iScience ; 27(9): 110839, 2024 Sep 20.
Article en En | MEDLINE | ID: mdl-39318534
ABSTRACT
Post-coronavirus disease condition (PCC) continues to affect many people globally, yet there remains a lack of diagnostic biomarkers to distinguish PCC from those recovered from acute COVID-19. This study compared biomarkers between two age- and gender-matched groups PCC individuals and those recovered within three months of acute COVID-19 in 2020 (n = 85 each). Biomarkers were assessed 12-24 months after initial diagnosis, examining biochemical profiles, blood cell counts, coagulation status, antibody serology, lymphocyte populations, and cytokine levels. PCC individuals exhibited significant alterations in 49 of 167 markers, including K+ levels, αGAD antibodies, antithrombin III, insulin-like growth factor-binding protein 3 (IGFBP3), and interleukin-10 (IL-10). A panel of αGAD, IL-10, potassium levels, and CD16brightCD56- cell presence distinguished PCC individuals from recovered patients with >88% accuracy and <92% precision.
Palabras clave